333
Participants
Start Date
December 31, 2007
Primary Completion Date
December 31, 2010
Study Completion Date
March 31, 2011
Certolizumab pegol
400 mg certolizumab pegol given every 4 weeks and placebo given every 4 weeks given as two injections (alternating injections every two weeks)
Certolizumab pegol
200 mg certolizumab pegol and placebo administered every 2 weeks (one injection of each)
Placebo
placebo (saline) administered as two injections every 2 weeks
Huntsville
Montgomery
Gilbert
Paradise Valley
Tucson
Little Rock
Huntington Beach
La Jolla
Los Angeles
Palm Desert
Sacramento
San Diego
Colorado Springs
Aventura
Clearwater
Gainesville
Jacksonville
Jupiter
Melbourne
Sarasota
Bogart
Morton Grove
Vernon Hills
Lexington
Portland
Haverhill
Pittsfield
Worcester
Rochester
Kansas City
Lincoln
Las Vegas
Reno
Albany
Mineola
Syracuse
Charlotte
Monroe
Wilmington
Cleveland
Perrysburg
Norman
Oklahoma City
Duncansville
Simpsonville
Dallas
San Antonio
Sugar Land
Tyler
Vancouver
Victoria
Winnipeg
St. John's
Burlington
Saint Catherine's
Toronto
Saskatoon
Bobigny
Le Havre
Lille
Limoges
Montivilliers
Nice
Paris
Perpigan
Saint-Etienne
Lead Sponsor
UCB Pharma
INDUSTRY